US biotech Gilead Sciences has announced that the US Food and Drug Administration (FDA) has accepted its New Drug Application ...
Danish pharma major Novo Nordisk has sued KBP Biosciences and its founder and executive chairman, Huang Zhenhua, for $830 ...
Kelso Pharma, the British specialty pharma business backed by Apposite Capital, today announced the acquisition of the UK ...
The US Food and Drug Administration (FDA) has granted Breakthrough Therapy designation (BTD) to Dutch clinical-stage drug ...
Barcelona, Spain-based biotech Ona Therapeutics today announced key leadership appointments to support its rapid growth and ...
Nura Bio, a US biopharma developing neuroprotective, small molecule therapies for the treatment of debilitating neurological ...
Israel-based clinical-stage company Purple Biotech today announced it is advancing into a Phase II study with NT219 in ...
US clinical-stage biotech Septerna yesterday announced its decision to discontinue the Phase I single- and multiple-ascending dose (SAD/MAD) clinical trial of SEP-786 in healthy volunteers. SEP-786 is ...
Epitopea, an Anglo-Canadian company developing accessible, off-the-shelf RNA-based immunotherapies for cancer, has announced a license and research collaboration deal with US pharma giant Merck & Co ...
According to new research announced today, the fragile X syndrome (FXS) market across the USA and Germany is projected to ...
Swiss dermatology company Galderma has announced two European approvals for Nemluvio (nemolizumab) to treat both atopic ...
Stoke Therapeutics’ stock climbed 8% early Tuesday, after the company and Biogen today announced a collaboration to develop ...